U.S. stock market midday update: Gelteq down 12.90% with increased trading volume, market sentiment fluctuations raise concerns, subsequent trends need to be observed cautiously

U.S. Stock Market Midday Update Gelteq, down 12.90%, with increased trading volume, and no significant news recently. The trading is active, with clear capital flow. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation. Stocks with High Trading Volume in the Industry Eli Lilly up 1.35%, with increased trading volume. Based on recent key news: On January 16, Eli Lilly announced the establishment of an artificial intelligence joint laboratory with NVIDIA, planning to invest up to $1 billion to accelerate drug development, driving the stock price up. This move reflects the company's strategic layout in the AI healthcare field and enhances market confidence in its future growth. (Jin Shi Data) On January 14, Eli Lilly stated at the JP Morgan Healthcare Conference that it is prepared for the market launch of its oral weight loss drug, expecting to capture more than one-third of the GLP-1 weight loss drug market share. This news has boosted investor optimism regarding Eli Lilly's position in the weight loss drug market. (First Financial) On January 13, South China Morning Post reported intensified competition in China's weight loss drug market, with Eli Lilly's tirzepatide injection price dropping significantly by about 80%. This move may affect its market share but also demonstrates the company's proactive response in the price war. (South China Morning Post) The commercialization of AI healthcare is accelerating, and the industry outlook is optimistic. Novo Nordisk up 8.34%. Based on recent key news: On January 16, Novo Nordisk's Wegovy oral drug launched in the U.S. achieved positive early prescription data, driving the stock price up. Analysts noted that the drug had approximately 4,290 prescriptions in the early launch phase, far exceeding competitor Eli Lilly's Zepbound, indicating strong market demand for the new drug. (Source: Zhitong Finance) On January 14, Novo Nordisk's CEO stated that the company is actively seeking acquisition deals to strengthen its obesity product portfolio. This move is seen as an important step in the company's strategic expansion, enhancing investor confidence in the company's future growth. (Source: Bloomberg) On January 16, UBS raised Novo Nordisk's target stock price to 390 Danish Krone, reflecting market optimism regarding the successful launch of its new drug. (Source: Jin Shi Data) The competition in the weight loss drug market is fierce, and risks should be monitored. Johnson & Johnson down 0.44%. Based on recent key news: On January 16, Johnson & Johnson MedTech signed an upgraded strategic cooperation agreement with domestic medical innovation company Changyida to promote research and development in the neurointervention field. This collaboration may enhance Johnson & Johnson's competitiveness in the medical technology sector, attracting investor attention. On January 15, Johnson & Johnson's TECVAYLI monotherapy showed superior progression-free survival and overall survival rates in multiple myeloma patients compared to standard treatments. This clinical data may enhance market confidence in Johnson & Johnson's drug development capabilities. On January 14, Johnson & Johnson faces challenges from generic drugs, as a large influx of generics is expected after the patent expiration of its blockbuster drugs, which may lead to a significant short-term decline in sales of the original drugs. This risk may affect investor expectations for Johnson & Johnson's future revenue The healthcare industry is facing challenges from generic drugs and needs attention. Stocks ranked at the top of the industry market capitalization AstraZeneca rose by 0.18%. Based on recent key news: On January 14, AstraZeneca announced the acquisition of Modella AI to enhance its oncology drug development capabilities. This move will promote the application of multimodal AI foundational models in the global oncology portfolio, helping to accelerate clinical development. On January 13, due to the launch of the "Billion Cell Atlas" by Menarini, AstraZeneca participated as a member of the alliance, promoting drug target validation and AI model training to improve R&D efficiency. On January 14, AstraZeneca discussed its merger and acquisition strategy and weight loss product portfolio at the JPMorgan Healthcare Conference, expecting 2026 to be a catalyst year, with multiple high-value late-stage readouts driving the company's performance. The acceleration of AI applications in the industry and significant capital inflows are evident